Beta-tubulin III expression in prostate cancer.
Scand J Urol Nephrol
; 44(6): 371-7, 2010 Dec.
Article
em En
| MEDLINE
| ID: mdl-20831453
ABSTRACT
OBJECTIVE:
Beta-tubulin isotype III is a microtubule component associated with resistance to chemotherapy and poor outcome in various cancers. This study aimed to investigate its expression in prostate cancer and its role as a prognostic factor in this setting. MATERIAL ANDMETHODS:
A tissue microarray was constructed of 289 prostate cancers from radical prostatectomy specimens with a median follow-up of 48.9 months. Slides were immunostained for ß-tubulin III. The intensity and extent of immunoreactivity and their product [immunoreactivity product (IRP)] were evaluated.RESULTS:
Tubulin III was expressed in the cytoplasm of prostate cancer cells but not in benign glands. Only 11.6% of cancers were positive for tubulin III. Among low-grade (Gleason score 5-6) and high-grade (Gleason score 7-10) cancers, 6.0% and 16.6% were positive, respectively (p = 0.006). ß-Tubulin III expression was more often seen in high-stage disease and more often in metastases (62.5%) than in primary lesions (11.6%) (p < 0.001). The intensity, extent and IRP of tubulin III all predicted biochemical recurrence in univariate Cox analysis (p = 0.02, p = 0.048 and p = 0.012, respectively). IRP was an independent predictor of prognosis when adjusted for serum prostate-specific antigen in a multivariate Cox analysis (p = 0.005), but not when the Gleason score was added to the model (p = 0.17).CONCLUSION:
ß-Tubulin III predicts biochemical recurrence after radical prostatectomy in a subset of patients. Its practical utility is limited by the low number of cases positive for this biomarker.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Tubulina (Proteína)
/
Biomarcadores Tumorais
Tipo de estudo:
Prognostic_studies
Limite:
Aged
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article